KORU Medical Systems, Inc. (NASDAQ:KRMD) Given Consensus Recommendation of “Moderate Buy” by Brokerages

KORU Medical Systems, Inc. (NASDAQ:KRMD) has received an average recommendation of “Moderate Buy” from the five research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $7.25.

A number of equities analysts have recently weighed in on KRMD shares. B. Riley Financial boosted their price objective on shares of KORU Medical Systems from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of KORU Medical Systems in a research note on Tuesday, April 21st. Canaccord Genuity Group reissued a “buy” rating and issued a $6.00 price target on shares of KORU Medical Systems in a research note on Friday, March 13th. Finally, Wall Street Zen lowered KORU Medical Systems from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th.

KORU Medical Systems Stock Performance

KORU Medical Systems stock opened at $4.10 on Friday. The firm has a market capitalization of $188.31 million, a price-to-earnings ratio of -82.00 and a beta of 0.43. KORU Medical Systems has a fifty-two week low of $2.63 and a fifty-two week high of $6.61. The stock’s fifty day moving average is $4.18 and its two-hundred day moving average is $4.84.

KORU Medical Systems (NASDAQ:KRMD) last released its earnings results on Thursday, March 12th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.01. The company had revenue of $10.90 million for the quarter, compared to analyst estimates of $10.90 million. KORU Medical Systems had a negative net margin of 5.27% and a negative return on equity of 13.61%. As a group, sell-side analysts forecast that KORU Medical Systems will post -0.04 EPS for the current fiscal year.

Hedge Funds Weigh In On KORU Medical Systems

Large investors have recently modified their holdings of the company. BNP Paribas Financial Markets raised its holdings in shares of KORU Medical Systems by 52.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company’s stock worth $39,000 after purchasing an additional 3,478 shares during the period. Lazard Asset Management LLC purchased a new position in shares of KORU Medical Systems in the 2nd quarter worth about $59,000. Arrowstreet Capital Limited Partnership purchased a new position in shares of KORU Medical Systems in the 1st quarter worth about $79,000. Occudo Quantitative Strategies LP purchased a new position in shares of KORU Medical Systems in the 4th quarter worth about $127,000. Finally, Invesco Ltd. acquired a new position in KORU Medical Systems during the 2nd quarter worth approximately $80,000. 58.60% of the stock is currently owned by hedge funds and other institutional investors.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.